Methodology for Developing Deprescribing Guidelines: Using Evidence and GRADE to Guide Recommendations for Deprescribing
Open accessThe DOI matches its Crossref record; 40 of the 42 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Class specific deprescribing guidelines could help clinicians taper and stop medications no longer needed or which may be causing more harm than benefit. We set out to develop methodology to create such guidelines using evidence-based methods for guideline development, evidence synthesis and recommendation rating. METHODS AND FINDINGS: Using a comprehensive checklist for a successful guideline enterprise, we conducted a national modified Delphi consensus process to identify priorities for deprescribing guidelines, then conducted scoping exercises to identify feasible topics, and sequentially developed three deprescribing guidelines. We selected guideline development team members for clinical expertise; a GRADE member worked with staff to ensure guideline development processes were followed. We conducted or used systematic searches and reviews of deprescribing trials of selected drug classes, reviews or systematic reviews of drug class effectiveness, reviews of reviews of drug class harm and narrative syntheses of contextual questions to inform recommendations and guideline development. Our 8 step process for guideline development included defining scope and purpose, developing a logic model to guide the process and generate key clinical questions, setting criteria for admissible evidence and conducting systematic reviews, synthesizing evidence considering additional contextual information and performing quality estimates, formulating recommendations and providing strength estimations, adding clinical considerations, conducting clinical and stakeholder review and finally updating content pre-publication. Innovative aspects of the guideline development process included synthesizing evidence for outcomes of tapering or stopping medication, and incorporating evidence for medication harm into the recommendation strength rating. Through the development of three deprescribing guidelines (for proton pump inhibitors, benzodiazepine receptor agonists and antipsychotics) and associated decision-support algorithms, we were able to gradually hone the methodology; each guideline will be published separately. CONCLUSION: Our methodology demonstrates the importance of searching for short and long-term outcomes, showing the benefits of deprescribing and studying patient preferences. This publication will support development of future deprescribing guidelines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Studies assessing the effect of abrupt versus gradual withdrawal [43,53,54,55,56] show that the withdrawal syndrome observed in the case of abrupt discontinuation makes it very difficult to stop the use of these molecules, especially in the case of short half-life BZDs. These studies recommend reducing BZD consumption over a period of at least 4 weeks.”
From Cognitive behavioral therapy and acceptance and commitment therapy for the discontinuation of long-term benzodiazepine use in insomnia and anxiety disorders (2021) · cites this paper as [54]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Scoping studies: towards a methodological framework
Arksey, H., & O'Malley, L. (2005) · International Journal of Social Research Methodology · doi:10.1080/1364557032000119616 · Cited by 36,742 · cited 1×
“We conducted scoping exercises to identify three of the top five priority topics for which deprescribing guideline development would be feasible [21].”
MethodLiberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048 · cited 1×
“They used the Cochrane methodological expectations for conduct of intervention reviews and the Cochrane handbook [27] and reported results of reviews using the PRISMA (Preferred Reporting in Systematic Reviews and Meta-Analyses) reporting guidelines with a PRISMA flow chart[28].”
MethodDermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · BMJ · doi:10.1136/bmj.b2700 · Cited by 17,648
GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables
Guyatt, G., Oxman, A. D., Akl, E. A., Kunz, R., Vist, G., Brozek, J., Norris, S., Falck-Ytter, Y., Glasziou, P., & deBeer, H. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.04.026 · Cited by 10,681
GRADE guidelines: 3. Rating the quality of evidence
Balshem, H., Helfand, M., Schünemann, H. J., Oxman, A. D., Kunz, R., Brozek, J., Vist, G. E., Falck-Ytter, Y., Meerpohl, J., & Norris, S. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.015 · Cited by 8,285 · cited 1×
“Each GDT used the GRADE approach to provide a formal rating of the synthesized evidence from the systematic review for the selected critical and important outcomes of deprescribing [29] (e.”
MethodAGREE II: advancing guideline development, reporting and evaluation in health care
Brouwers, M. C., Kho, M. E., Browman, G. P., Burgers, J. S., Cluzeau, F., Feder, G., Fervers, B., Graham, I. D., Grimshaw, J., Hanna, S. E., et al. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.090449 · Cited by 3,790 · cited 3×
“A practicing family physician, nurse practitioner and pharmacist (who were not members of the Deprescribing project) provided a clinical review of each guideline using the AGREE II Global Rating Scale [33] to guide their evaluation in rating the scope and purpose of the guideline, stakeholder involvement, rigour of de…”
MethodInfluentialNorderyd, O. M., Koch, G., Papias, A., Köhler, A. A., Helkimo, A. N., Brahm, C., Lindmark, U., Lindfors, N., Mattsson, A., Rolander, B., et al. (2015) · PubMed · Cited by 3,584
By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel (2015) · Journal of the American Geriatrics Society · doi:10.1111/jgs.13702 · Cited by 2,609
Research works printed but not linked: 1
- Lemay G, Dalziel B. Better prescribing in the elderly. 2012; 2(3): 20– 6.
Cited by
Items 101–134 of 134
Comment on: “Patient Perceptions of Opioids and Benzodiazepines and Attitudes Toward Deprescribing”
Langford, A. V., Schneider, C. R., Reeve, E., Doctor, J. N., & Gnjidic, D. (2024) · Drugs & Aging · doi:10.1007/s40266-023-01086-6 · Cited by 1
Evaluation of a Pharmacist-Led Proton Pump Inhibitor Deprescribing Process in an Acute Care Hospital
Wang, R., Methot, M., & Mistry, M. (2018) · TSpace (University of Toronto)
Deprescribing in der Dermatologie: Ein systematisches Review aktueller dermatologischer Leitlinien
Darr‐Foit, S., Elsner, P. U., & Tittelbach, J. (2019) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.13759_g
Moving From Recommendations to Impact in Post-acute and Long-term Care Research
Zimmerman, S. I., & Tandan, M. (2019) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2019.09.018
Kim, C. (2019) · TSpace (University of Toronto)
Kirilochev, O. O. (2020) · Advances in Gerontology · doi:10.1134/s2079057020040098
Langford, A. V., Schneider, C. R., Lin, C. C., & Gnjidic, D. (2022) · Pain · doi:10.1097/j.pain.0000000000002371
Part I: Interactive case: Rational deprescribing of benzodiazepine receptor agonists for insomnia
Farrell, B. J. (2022) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1612
Self-citationConklin, J., Farrell, B. J., Dilliott, D., Richardson, L. M., McCarthy, L. M., & Raman‐Wilms, L. (2022) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.1177/17151635221139830
“Deprescribing is the planned and supervised process of reducing or stopping medications that are no longer needed or where harm may outweigh benefit.(18) As we implemented these guidelines, health care providers also told us that deprescribing would be facilitated if their patients came to them with questions about wh…”
BackgroundSelf-citationRaman‐Wilms, L., Farrell, B. J., & Thompson, W. (2022) · Springer eBooks · doi:10.1007/978-3-030-50247-8_34-1
Self-citationRaman‐Wilms, L., Farrell, B. J., & Thompson, W. (2023) · Springer eBooks · doi:10.1007/978-3-030-50247-8_34-2
Self-citationDesprescrição de benzodiazepínicos: caminhos para o enfrentamento necessário
Baldoni, A. O., SILVA, L. R., & Pereira, M. L. (2023) · Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde · doi:10.30968/rbfhss.2023.143.1038
Cardoso, J. E. G., & Neto, A. A. B. (2025) · Revista Contemporânea · doi:10.56083/rcv5n2-053
Pétein, C., Chevallereau, T., Aikpitanyi, J., Evrard, P., Tubeuf, S., Henrard, S., & Spinewine, A. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-085434 · Cited by 1
“Interviews will be analysed using a deductive and inductive thematic approach using QRS NVivo V.11.”
Development and Implementation of Deprescribing Guidelines
Langford, A. V., Moriarty, F., Goordeen, D., Farrell, B. J., & Reeve, E. (2025) · Advanced clinical pharmacy - research, development and practical applications/Advanced clinical pharmacy - research, development and practical applications · doi:10.1007/978-3-031-77314-3_4 · Cited by 1
Self-citationGrede, N., Kuss, K., Staudt, I., Donner‐Banzhoff, N., & Viniol, A. (2024) · Figshare · doi:10.6084/m9.figshare.26564394
Salas, R., González, C. P. V., Eslava-Schmalbach, J., Torres-Espinosa, C., & Figueras, A. (2023) · Figshare · doi:10.6084/m9.figshare.24416178
Gupta, S., Tang, R., Petricca, K., Florez, I. D., & Kastner, M. (2022) · Figshare · doi:10.6084/m9.figshare.20342433
Grede, N., Kuss, K., Staudt, I., Donner-Banzhoff, N., & Viniol, A. (2024) · Figshare · doi:10.6084/m9.figshare.26564388
Salas, R., González, C. P. V., Eslava-Schmalbach, J., Torres-Espinosa, C., & Figueras, A. (2024) · Figshare · doi:10.6084/m9.figshare.24416279
Grede, N., Kuss, K., Staudt, I., Donner‐Banzhoff, N., & Viniol, A. (2024) · Figshare · doi:10.6084/m9.figshare.26564391
Salas, R., González, C. P. V., Eslava-Schmalbach, J., Torres-Espinosa, C., & Figueras, A. (2024) · Figshare · doi:10.6084/m9.figshare.26629651
Gupta, S., Tang, R., Petricca, K., Florez, I. D., & Kastner, M. (2022) · Figshare · doi:10.6084/m9.figshare.20342439
Gupta, S., Tang, R., Petricca, K., Florez, I. D., & Kastner, M. (2022) · Figshare · doi:10.6084/m9.figshare.20342436
Salas, R., González, C. P. V., Eslava-Schmalbach, J., Torres-Espinosa, C., & Figueras, A. (2024) · Figshare · doi:10.6084/m9.figshare.26629654
Additional file 1 of Evidence for deprescription in primary care through an umbrella review
Lima, A. O. D. L., Marcos‐Marcos, J., Márquez, A. M., Vera, M. D. L. Á. G., Matas Hoces, A., & Bermúdez‐Tamayo, C. (2020) · Figshare · doi:10.6084/m9.figshare.12450446
Sanyal, C., Watema-Lord, R., & Xie, F. (2026) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.70166
“Various strategies for effective deprescribing have been developed including drug-specific guidelines, educational programs, medication reviews, and audits of prescribing practices [9, 10].”
Wastesson, J. W., Willers, C., Kamgang, K. S., Björk, T., Fastbom, J., Johnell, K., & Lundby, C. (2026) · Äldre i Centrum Vetenskapligt supplement · doi:10.52585/icvs.v6i1.26
Deprescribing in Clinical Practice: Evidence, Implementation, and the Role of Pharmacists
Liau, S. J., Falconer, N., Liu, B. M., Scott, I. A., Hilmer, S. N., & Reeve, E. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-26472-6.00008-5 · Cited by 1
Filosa, E., Schönenberger, N., Essien, U. R., Gagnon, C. L., Gnjidic, D., O’Donnell, L. K., Manias, E., McCarthy, L. M., Moriarty, F., Nguyen‐Soenen, J., et al. (2026) · JMIR Research Protocols · doi:10.2196/92082
Langford, A. V., Liau, S. J., Loh, S., Farrell, B. H., Thompson, W., Pollock, D., Moriarty, F., Gnjidic, D., Ailabouni, N. J., & Reeve, E. (2026) · Journal of General Internal Medicine · doi:10.1007/s11606-026-10679-x · Cited by 2
Self-citationAckermans, L., Durme, T. V., de Saint‐Hubert, M., Guisset, S., Leeuwen, E. V., Coteur, K., Tommelein, E., Philippe, G., Dilles, T., Verschuren, S., et al. (2026) · Journal of General Internal Medicine · doi:10.1007/s11606-026-10724-9
Haußmann, R., & Borchers, R. (2026) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-2946-3364
Metadata
- Authors
- Farrell, B., Pottie, K., Rojas-Fernandez, C. H., Bjerre, L. M., Thompson, W., & Welch, V.
- Affiliations
- University of Waterloo (CA)
- University of Ottawa (CA)
- Corresponding author
- Farrell, Barbara
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-08-12
- Volume
- 11
- Issue
- 8
- Pages
- e0161248
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4982638
- OpenAlex
- W2510306467
- Cited by
- 134
- References
- 42
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 10 · 2023: 25 · 2022: 17 · 2021: 7 · 2020: 21 · 2019: 13 · 2018: 18 · 2017: 8
- FWCI
- 7.49
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- uO Research (University of Ottawa) (submittedVersion, public-domain)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- University of Ottawa - Library
- Funders
- Government of Ontario (#06674)
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Clinical practice guidelines implementation
- Health Sciences › Health Professions › General Health Professions › Healthcare cost, quality, practices
- Keywords
- deprescribing, guideline development methodology, GRADE, strength of recommendation, medication tapering, drug-related harm, proton pump inhibitors, benzodiazepine receptor agonists, antipsychotic drugs, decision support algorithm, Delphi consensus, evidence synthesis, patient preferences
- MeSH terms
- Deprescriptions, Health Services Needs and Demand, Humans, Drug Prescriptions, Practice Guidelines as Topic, Evidence-Based Medicine, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.